17189-Ovarian Cancer-NA-1530

Ovarian Cancer

The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer (VB-111-701 / GOG-3018)

  • Details

ClinicalTrials.gov ID: NCT03398655
Diagnosis Type: NA
USOR Number: 17189

  • Address

7695 South Research Dr
Tempe, AZ 85284
P: (888) 972-2873

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.